Polish Physicians’ Perspectives on Medical Cannabis Policy and Educational Needs: Results of An Online Survey

Martyna Hordowicz 1,2,*, Jerzy Jarosz 2, Małgorzata Czaplińska 1,2,3, Agnieszka Leonhard 1,2 and Anna Klimkiewicz 2,3

1 Hospice of St. Christopher in Warsaw, 02-781 Warsaw, Poland; malgorzata.czaplinska@fho.org.pl (M.C.); agnieszka.leonhard@fho.org.pl (A.L.)
2 Polish Society of Medical Cannabis and Cannabinoids, 02-781 Warsaw, Poland; jerzy.jarosz@op.pl (J.J.);
anne.klimkiewicz@wum.edu.pl (A.K.)
3 Medical Faculty, Medical University of Warsaw, 02-781 Warsaw, Poland
* Correspondence: m.hordowicz@gmail.com

Abstract: (1) Background: In November 2017, medical cannabis was legalized in Poland. Until now, there have been no studies conducted to examine the perspectives of Polish physicians about their preferences regarding medical cannabis legal status and educational needs. (2) Methods: The survey was a self-developed online questionnaire with 57 participants. Participation was voluntary. The link was shared through a personal network of medical doctors, regional medical chambers, and with doctors attending palliative care courses organized by our research group. Results: Between June and October 2020, 173 HCPs from Poland completed the survey. More than half of the study participants never received any education on medical cannabis (60.1%); 71.1% declared their knowledge was insufficient to counsel patients about medical cannabis use. The majority claimed that they would like to be able to answer patient questions (92.4%); 93.1% declared a need to create clear guidelines for using cannabinoids in clinical practice. Furthermore, 71.7% believed that medicines containing cannabinoids and 52.0% that herbal cannabis should be reimbursed (3). Conclusion: Most medical doctors do not feel prepared for patient counseling. They could benefit from targeted educational interventions. We have also identified physicians’ preferences that might inspire the stakeholders involved who are critical for shaping policies regarding cannabis-based therapeutics.

Keywords: medical cannabis; Poland; physicians; perspectives; survey; cannabinoids; education

1. Introduction

On the 1 November 2017, the legal status of herbal cannabis in Poland changed. It became legal as a pharmaceutical raw material for preparing prescription drugs material under the Act of Counteracting Drug Addiction in Poland [1]. Physicians may prescribe cannabis under the same conditions as other controlled substances. Several strains are available in Poland, with varying THC: CBD (tetrahydrocannabinol: cannabidiol) ratio and terpenoid and flavonoid profile. Sativex, oromucosal spray with THC, i.e., a CBD ratio close to 1:1, is also registered in Poland for symptom improvement in auld patients with moderate to severe spasticity due to MS (multiple sclerosis) [2,3]. The Ministry of Health (MoH) did not grant the refund to any medicine containing cannabinoids, which means that the patients pay the total, relatively high cost of treatment. There were only a few exceptions where patients were granted financing from MoH through a compassionate use program.

Current Polish regulations classify THC as a substance with a high probability of abuse and low therapeutic value (II-P group). Herbal cannabis, other than fiber-type cannabis (with THC content $\geq 0.2\%$), is classified under the I-N category, defined as a substance with high abuse potential, which may have therapeutic applications [4,5]. There are no defined limits on the quantity of possessed cannabis for treatment purposes. However, it should be
no higher than the amount required for 90 days of treatment, which is calculated based on
dosing on the prescription of THC, with no upper limit; this regulation does not apply to
other cannabinoids, such as CBD [6].

The cultivation of cannabis, including culture by patients’ medical needs, is not
allowed on Polish territory. Therefore, the whole market relies on deliveries of cannabis
from foreign countries by marketing authorization holders (MAHs) registered in Poland,
originating from Canada or Germany. The sole exception is the culture of cannabis for
research purposes, but such permission is granted only in exceptional situations by the
Chief Sanitary Inspectorate [6].

The Polish the Agency for Health Technology Assessment and Tariffication (HTA&T)
has repeatedly recommended against reimbursement of herbal cannabis on numerous
conditions: chemotherapy-induced nausea and vomiting; multiple sclerosis; chronic pain;
epilepsy, including treatment-resistant epilepsy; Dravet syndrome; Jacobsen syndrome, and
glaucoma due to Sturge–Weber Syndrome [7–10]. All the HTA&T statements point out that
there is no evidence demonstrating the effectiveness of specific, CBD-rich cannabis strains
in refractory epilepsy. However, they admit that there is evidence of the benefits of this
active compound from clinical trials of other medicines in both Dravet and Sturge–Weber
Syndromes [7,8]. A similar narrative the HTA agency used to decline reimbursement of
THC-containing strains of cannabis (with or without CBD) in indications such as chronic
pain, complex regional pain syndrome (CPS), and phantom pain. The agency admitted
that the available evidence is limited and does not justify any form of copayment (i.e.,
reimbursement) by the Ministry of Health [10].

The regulations regarding treatment with cannabinoids are murky and split into
numerous law acts; as a result, many physicians avoid prescribing cannabis, even when
the treatment has already been prescribed by another qualified healthcare professional.
Technically, every medical doctor in Poland is permitted to prescribe cannabis, regardless
of having a specialist’s title or professional training, similarly to other medicines based
on controlled substances, such as opioids [1,2,4–6]. On the other hand, the decision to
initiate treatment and the responsibility for choosing proper indication and dosing relies
solely on the prescribing physician because no official guidelines define these [11]. Patients
receiving cannabinoids as therapy do not obtain official documents, such as certificates. No
registry of patients taking cannabinoids exists to track prescriptions, overall consumption
rates, or outcomes. There are also no official lists of physicians authorized to prescribe
 cannabis [1,2,4–6]. No independent source of education for physicians is available, and the
medical uses of cannabinoids and the physiological basis of their mode of action are not
part of medical curricula for medicine students. In the current setting, prescribing cannabis
might be considered risky, especially given the lack of educational resources available to
the HCPs. To date, no studies have been conducted in Poland to reveal the educational
needs and preferences for systemic solutions to control the medical cannabis market.

Surveys regarding medical cannabis were conducted worldwide among certified med-
ical doctors, pharmacists, and medical faculty students [12–30]. Most of these studies reveal
problems with the lack of local clinical standards or knowledge about the legal status of
medical cannabis [12,13]. In studies that included such questions, most respondents ranked
their level of knowledge as low or insufficient in the context of clinical practice [14–17].
Furthermore, both students of medical faculties, including medicine, nursing, or pharmacy,
and certified physicians declare they would like to receive more education. The students
participating in these studies from other European countries (Spain, Poland, Serbia) also
admit that they would like to have some classes at the university [19–21]. Previous studies
demonstrate that, although most medical doctors accept using cannabis for medical reasons,
recreational uses do not get as much support. Studies also show that views vary by medical
specialty, gender, age, and religiosity [12,13]. Oncologists and palliative care specialists
usually advocate strongly for the use of medical cannabis, family medicine, and neurology
specialists are more conservative [12,13,22–28]. There are also slight differences in the
acceptance of incorporating cannabinoids in clinical practice between doctors and medical
students living in different geographical locations [12]. In both studies conducted among general practitioners in Ireland or Minnesota, 58% of physicians supported the legalization of cannabis for therapeutic purposes, and among Spanish nursing students—75% [18,19,23]. In Eastern Europe, this proportion was generally lower, reaching 33% in medical students of Belorussian origin. In Russia, only 26% of male students of medicine declared they would recommend medical cannabis to a patient in the event of its legalization [12]. These differences might be explained by personal experiences, professional training, and cultural differences. Previous studies have shown profound differences in illicit drugs and alcohol consumption among different European countries. There are also significant differences between the consumption of controlled substances in medicine between Eastern (less than 1000 defined daily dose (DDD) of morphine) and Western Europe (over 10,000 DDD) [29].

Medical cannabis remains an ongoing controversy in conservative countries of East-Central Europe; however, none of the studies mentioned above involved medical doctors from Poland. Poland has been a member of the United Nations (UN) since 1999, and of the European Union (EU) since 2004. Considering that the average age of medical doctors in Poland in 2017 was 52 years [30], and the time required to acquire specialist training, most attended university in the 80’s. At that time, Poland was still under Soviet influence, which ended after 1989. Therefore, Polish citizens in recent decades have been under the influence of contrary cultures, which shaped their beliefs, perspectives, and actions. We decided to investigate their views on medical cannabis and legislative solutions and their self-evaluated knowledge level, educational needs, and motives for expanding their knowledge on medical applications of cannabinoids. This study aims to provide insights from medical practitioners to inform their views on the medical cannabis policy in Poland approximately three years after its legalization. We aim to use the results to inform relevant stakeholders about educational activities necessary to increase competence and knowledge and to motivate physicians to attend such events.

2. Materials and Methods

This study report was written based on the the Checklist for Reporting Results of Internet E-Survey (CHERRIES) guidelines [31]. It was an open survey, and participation was voluntary. Access to the questionnaire was only possible through a direct link. We offered no incentives for participation.

2.1. Survey Development

We initially aimed to perform the survey in traditional (paper) form; however, the form was switched to digital because of the coronavirus pandemic outbreak. We used Google Forms as a data collection platform. Two medical doctors from the research group tested the online survey before the links were shared with participants. They introduced minor corrections to the wording and mechanics of the survey, i.e., type of questions.

We based the survey on two self-developed questionnaires. One was previously distributed during a conference about medical cannabis in January 2019 organized by Hospice of St. Christopher in Warsaw. Questions regarding systemic solutions were adapted from that survey. These questions asked about the attitude towards medical cannabis legalization and formal restrictions and requirements for cannabis prescribing. The second survey was developed to investigate attitudes and knowledge about opioids among physicians, commissioned by the National Bureau for Drug Prevention (NBDP). Results from the survey about opioids were reported separately (the report is owned by NBDP and is not publicly available). We adapted and adjusted the questions regarding clinical aspects from that questionnaire on opioids, but we plan to report these results in a separate paper.

2.2. Survey Design

The study’s aims, information about the researchers’ organization, and a short survey description were displayed before the questions. The study questionnaire consisted of
57 items grouped in five parts: demographic data, legal aspects, and access to medication containing cannabinoids; cannabinoids‘ use; clinical practice; educational needs; and personal experiences with controlled substances. There were open questions (about medical specialty or to allow participants to explain their answer in more detail) and closed questions (some using Likert 5-point scale or single- and multiple-choice answers). Questions were not randomized. The survey form forced its completion before submitting the result. All participants could check and correct their answers before submitting.

2.3. IRB Approval

The study protocol was prepared in line with the recommendations of the Helsinki Declaration. It was approved by the Bioethics Committee of the Medical University of Warsaw (IRB statement from the 3 February 2020, number AKBE/22/2020).

2.4. Participants

The survey participants were medical doctors with or without specialization. The participants were recruited from June to October 2020 in the following ways:

- From an online palliative medicine course in June and October 2020, which our research group organized in the Hospice of St. Christopher in Warsaw.
- From a closed Facebook group for young medical doctors during specialization (Residents) known as “Residents Agreement”, with the group’s owner verifying the professional background of group members.
- Through a newsletter for medical doctors known as “Young Medical Professionals”, led by an organization which helps in the preparation of professional examination for prospective physicians.
- Through a personal network of physicians from different medical backgrounds.
- We sent a request to share the link to the questionnaire with all regional medical chambers in Poland. There are 16 chambers, one in each voivodeship. It is currently mandatory that each medical doctor is a member of one located in his primary workplace. Each has its website and a newsletter sent to every member.

The diversity of sources should enable the participation of a broad group of physicians representing different medical backgrounds from different age groups and geographical localization. In Poland, there are essential differences in terms of political preferences, religiosity between the eastern and western parts of Poland, with the east being more conservative and catholic and the west showing contrary tendencies. These factors influence choices and opinions about cannabis; therefore, it was vital to reach physicians using various channels.

We did not collect personal and contact data. To ensure the complete anonymity of the survey users, the IP was not collected. Each set of answers was reviewed manually for completeness and any random/accidental entries. None were identified.

We would exclude any entries made by physicians or double entries identified based on the open-ended answers. There were no exclusion criteria in terms of time spent on filling out the questionnaire. The survey forced the respondent to fill out all fields, and incomplete records were not saved.

2.5. Statistical Analysis

Statistical analysis was performed using the IBM SPSS Statistics ver. 26 (IBM Corp., Armonk, NY, USA). An analysis of basic descriptive statistics was performed.

3. Results

3.1. Response Rates

Due to the limitations of the online platform, which does not enable the removal of duplicates, it was necessary to review all records manually. Because some questions (e.g., medical specialty, years of practice, answers to some questions in the clinical part) had to
be introduced by the survey participant in writing (e.g., medical specialties), it was possible to identify unique visitors. No duplicates were found.

3.2. Basic Characteristics

Between June and October 2020, 173 physicians from Poland completed the survey. Most participants (n = 150; 86.7%) were less than 50 years old and lived in large cities with more than 100,000 inhabitants (n = 112; 64.7%). Only a limited proportion declared they work mainly in the private sector (n = 36; 20.8%). The most common MDs with specialist titles were general practitioners (GPs), internal medicine, and oncology-related.

The participants were from 15 out of 16 voivodeships (macroregions) of Poland. A similar proportion of participants were recruited from western voivodeships in Poland (n = 66; 38.15%), central (n = 59; 34.1%), and eastern regions (n = 48; 28.78%). We presented other characteristics of the study participants in Table 1.

| Table 1. Demographic data. |
|-----------------------------|
| Age Group                   | <30 Years | 41 | 23.7 |
|                             | 30–39 years | 76 | 43.9 |
|                             | 40–49 years | 33 | 19.1 |
|                             | 50–65 years | 23 | 13.3 |
| Gender                      | Male | 59 | 34.1 |
|                             | Female | 114 | 65.9 |
| Medical background           | Internal medicine (and associated specialties) | 38 |
|                             | GP | 20 |
|                             | Oncology and hematology (e.g., radiotherapy, oncology surgery) | 14 |
|                             | Psychiatry | 11 |
|                             | Anesthesiology and intensive therapy | 16 |
|                             | Neurology (adult and pediatric) | 7 |
|                             | Gynecology | 5 |
|                             | Surgical | 6 |
|                             | Palliative care | 3 |
|                             | Hematology | 2 |
|                             | None/during medical training (unspecified) | 28 |
|                             | Other | 24 |
|                             | pediatrics | 7 |
|                             | Medical internship | 5 |
| Primary workplace            | Town/villages up to 10,000 habitants | 12 | 9 |
|                             | Towns from 10–20,000 habitants | 15 | 8.7 |
|                             | Cities 20–50,000 habitants | 9 | 5.2 |
|                             | Larger cities 50–100,000 habitants | 25 | 14.5 |
|                             | Large cities | 112 | 64.7 |
| Primary sector               | Public | 136 | 78.6 |
|                             | Private | 36 | 20.8 |
|                             | No data | 1 | 0.6 |
| Contact with persons with addictions | Yes | 76 | 43.9 |
|                             | No | 97 | 56.1 |
3.3. Education Level on Cannabinoids and Medical Cannabis

More than half of the study participants never received any education regarding medicinal cannabis (n = 104; 60.1%). The most mentioned educational activity was a lecture about cannabinoids attended at a conference dedicated to another medical subject (n = 49). Few participants participated in a conference (n = 7), or a course (n = 10) dedicated entirely to medical cannabis and cannabinoids before taking part in the study. When asked if their knowledge was sufficient to counsel patients on medical cannabis use, roughly 10% of doctors said they did (17/173) and 71.1% (123/173) said they did not. More details can be found in Table 2.

Table 2. Education on medical cannabis and cannabinoids.

| Answer | N (%) |
|--------|-------|
| No | 104 (60.1%) |
| Yes | 69 (39.9%) |

| What kind of education was it? * | N |
|---------------------------------|---|
| A conference dedicated to cannabis/cannabinoids | 7 |
| Course on medical cannabis and cannabinoids | 10 |
| A lecture on cannabinoids during another conference | 49 |
| Other | 22 |

| Do you believe your knowledge is sufficient to counsel patients on cannabinoid use? | N (%) |
|------------------------------------------------|-------|
| No | 80 (46.2%) |
| Rather not | 43 (24.9%) |
| Neither agree nor disagree | 33 (19.1%) |
| Rather yes | 12 (6.9%) |
| Yes | 5 (2.9%) |

* the number exceeds the number of participants declaring past training in cannabinoids as some marked more than one answer.

For the questions which used a 5-point Likert scale for assessment, we decided to group the answers to ease the interpretation. We ranked 4 and 5 as “agree”, 3 as “neutral opinion”, and 1 to 2 as “disagree”. In terms of the motivation for increasing knowledge on medical cannabis and cannabinoids, most frequently, the doctors claimed that they would like to be able to answer patient questions (160/173; 92.4%) and discuss their experiences with other medical professionals (159/173; 91.9%). Another reason frequently chosen was to seek new treatments for patients for whom other treatments do not provide sufficient relief or the side effects are intolerable (145/173; 83.8%). A similar number of participants declared having safety concerns (69/173; 39.9%) and denied having any (66/173; 38.2%). Personal motivation was the least motivating; only 38 participants agreed or partly agreed with that statement (22.0%). Only 38 participants (22%) declared that they were not interested in increasing their knowledge of medical cannabis. Table 3 shows the motives for further education on cannabinoids.
Table 3. Motivation for expanding knowledge on medical uses of cannabinoids.

| Motivation                                                                 | 1— Disagree | 2— Partly Disagree | 3— Neither Agree Nor Disagree | 4— Partly Agree | 5— Agree | Mean | Median | Mode |
|---------------------------------------------------------------------------|-------------|---------------------|-------------------------------|----------------|----------|------|--------|------|
| I'm not interested in medical uses of cannabinoids                        | 110         | 25                  | 13                            | 12             | 13       | 1.8  | 1      | 1    |
| I would like to expand my knowledge and skills in the medical use of cannabis/cannabinoids | 3           | 5                   | 17                            | 47             | 101      | 4.38 | 5      | 5    |
| I would like to be able to answer patient questions about cannabinoids     | 4           | 3                   | 6                             | 49             | 111      | 4.5  | 5      | 5    |
| I would like to be able to consult cases from my clinical practice with other professionals | 3           | 3                   | 8                             | 53             | 106      | 4.48 | 5      | 5    |
| I would like to be able to verify my experiences and opinions related to cannabinoid containing products | 3           | 4                   | 11                            | 59             | 96       | 4.39 | 5      | 5    |
| I have some concerns about the safety of cannabinoids                      | 30          | 36                  | 38                            | 54             | 15       | 2.93 | 3      | 4    |
| Seeking new treatments for patients for whom current treatments are ineffective or intolerable | 6           | 5                   | 17                            | 49             | 96       | 4.29 | 5      | 5    |
| Personal motivation                                                        | 54          | 29                  | 52                            | 23             | 15       | 2.51 | 3      | 1    |

SD—standard deviation.

3.4. Systemic Solutions on Access to Medical Cannabis

Most study participants (161/173; 93.1%) declared a need to create clear guidelines for using cannabinoids in clinical practice. One hundred and twenty four participants (71.7%) believed that the Polish government should also reimburse medicines containing cannabinoids. Physicians showed less support for the herbal form of cannabis (90/173; 52.0%). Most doctors disagreed with the statement that an official request for cannabis treatment should be issued by a prescribing physician and approved by an officially established, empowered body before treatment initiation (142/173; 82.1%) or that, in all cases, the patient should be consulted by a psychiatrist before initiation of treatment with cannabinoids (108/173; 62.4%). The majority also disagreed that there should be a national registry of patients or doctors authorized to prescribe medical cannabis (90/173 in both cases; 52.0%). Fewer doctors disagreed (51/173; 29.5%) than agreed (85/173; 49%) that the prescription for cannabinoids should be issued only by a physician with training in cannabinoids use. It is worth noting that being a specialist was claimed necessary (72/173; 41.6%) and not necessary (79/173; 45.7%) by a similar proportion of physicians. We presented answers to the questions on systemic solutions in Table 4.
Table 4. Access to cannabinoid, systemic, medicine-related solutions.

| Do You Agree That                                                                 | 1—Disagree | 2—Partly Disagree | 3—Neither Agree Nor Disagree | 4—Partly Agree | 5—Agree | Mean | SD (±) | Median | Mode |
|-----------------------------------------------------------------------------------|-------------|--------------------|------------------------------|----------------|---------|------|--------|--------|------|
| any physician may prescribe medical cannabis and cannabinoids?                     | 32          | 26                 | 31                           | 35             | 49      | 3.25 | 1.48   | 3      | 5    |
| medical cannabis and medicines containing cannabinoids should be available to patients in selected indications only with a physician’s prescription with a specialist background? | 48          | 31                 | 22                           | 28             | 44      | 2.94 | 1.57   | 3      | 1    |
| medical cannabis and medicines containing cannabinoids should be available with a doctor’s prescription with special training (or certificate) in treating cannabinoids? | 31          | 20                 | 37                           | 38             | 47      | 3.29 | 1.44   | 3      | 5    |
| A request for cannabinoid treatment issued by a physician should be approved by a government or self-regulatory medical organization | 109         | 33                 | 17                           | 6              | 8       | 1.68 | 1.09   | 1      | 1    |
| initiation of cannabinoid treatment, regardless of the primary indication, should be consulted with a psychiatrist | 55          | 53                 | 30                           | 21             | 14      | 2.34 | 1.26   | 2      | 1    |
| there is a need for clear guidelines for medical cannabis/cannabinoid drug treatment | 1           | 2                  | 9                            | 28             | 133     | 4.68 | 0.68   | 5      | 5    |
| medicines containing cannabinoids should be reimbursed                              | 4           | 3                  | 42                           | 44             | 80      | 4.12 | 0.99   | 4      | 5    |
| herbal cannabis should be reimbursed                                                | 11          | 13                 | 59                           | 32             | 58      | 3.65 | 1.2    | 4      | 3    |
| there should be a national registry of people treated with cannabinoids            | 64          | 26                 | 37                           | 21             | 25      | 2.52 | 1.45   | 2      | 1    |
| there should be a national registry of physicians authorized to prescribe cannabinoids | 63          | 27                 | 33                           | 21             | 29      | 2.57 | 1.49   | 2      | 1    |

SD—standard deviation.

3.5. Recreational Drug Use

Questions about personal experiences with recreational drugs revealed that most of the participants were naïve about cannabis. Only 39.9% (n = 68) admitted having an experience with recreational cannabinoids, such as herbal cannabis and hashish. Most study participants (60.7%; n = 105) denied having any personal experience with cannabis. One of the participants claimed to be addicted to cannabis.
Those who admitted having used it consumed it for reasons other than medical (32.94%; n = 57). In addition, 82.1% (n = 142) declared that, if marijuana was legal, they would not use it for recreational purposes. Most agreed that cannabis can be addictive (90.2%; n = 156) and is harmful to human health (64.2%; n = 111); however, not with the statement that it might be a ‘gateway drug’ leading to abuse of hard drugs (59%; n = 102). Other results might are in Table 5.

Table 5. Past use of cannabis and other psychoactive substances.

|                                           | No          | Yes         | All         |
|-------------------------------------------|-------------|-------------|-------------|
| Have you used cannabinoids (marijuana, hashish) in the past? | 105 (60.7%) | 68 (39.9%)  | 173 (100%)  |
| If yes, have you used cannabinoids for medicinal purposes? | 57 (32.94%) | 11 (6.36%)  | 68 (39.3%)  |
| Do you think cannabinoids (marijuana, hashish) are dangerous to human health? | 93 (53.8%)  | 80 (46.2%)  | 173 (100%)  |
| Do you consider yourself to be addicted to cannabinoids? | 172 (99.4%) | 1 (0.6%)    | 173 (100%)  |
| Do you believe that cannabinoids (marijuana, hashish) can be addictive? | 17 (9.8%)   | 156 (90.2%) | 173 (100%)  |
| Do you think that the use of cannabinoids (marijuana, hashish) leads to the abuse of harder drugs? | 102 (59.0%) | 71 (41.0%)  | 173 (100%)  |
| Do you believe that marijuana/hashish is harmful to human health? | 62 (35.8%)  | 111 (64.2%) | 173 (100%)  |
| Do you think medical marijuana is safer than illegal cannabis products (“street cannabis”)? | 4 (2.3%)    | 169 (97.7%) | 173 (100%)  |
| Is it possible that when you have easy access to medical marijuana, you will reach for it for recreational purposes? | 142 (82.1%) | 31 (17.9%)  | 173 (100%)  |
| Have you used other psychoactive drugs in the past (e.g., opioids, LSD, ecstasy, psilocybin, legal highs), or are you currently doing so? | 109 (63.0%) | 21 (12.1%)  | 130 (75.1%) |

4. Discussion

As the medical cannabis market grows in Poland, it becomes essential to understand physicians' perspectives on this controversial topic. This study was the first performed among Polish physicians to investigate their beliefs about medical cannabis and views on the shape of policy in their country. Most participants (93.1%) confirmed a need to prepare medical guidelines about cannabinoids use. While most supported reimbursement of medicines containing cannabinoids (71.7%) for herbal cannabis, this percentage was lower (52%). We also found a legitimate need to provide educational interventions to train medical professionals in medical applications of cannabinoids and the physiological basis of their mode of action. Over 1/3 also declared that they have safety concerns regarding medical uses of cannabinoids (39.9%). It is worth noting that medicinal cannabis was also considered safer than one bought from illegal sources by the vast majority (97.7%); 71.1% claimed their knowledge level to be too low to provide advice to patients. Almost all physicians agreed (92.4%) that they would prefer to be more knowledgeable on this topic to fulfill patient’s expectations. The factors encouraging them to seek more information about medical cannabis and cannabinoids were mostly patient-centered (seeking new treatments for cases with no other acceptable therapeutic options, clarifying safety concerns). At the same time, most declared that personal motives are not a factor that could increase their willingness to learn more (only 22% agreed).

A lack of clear guidelines regarding medical applications of cannabinoids is one of the commonly listed barriers to cannabis use [12,16,22]; 93.1% of Polish physicians declared a need to formulate clear guidelines to inform physicians how to incorporate cannabinoids into their clinical practice. Similar findings come from studies conducted in other countries; 93% of prospective medical doctors from Serbia and 64% of physicians from Canada
also claimed that such guidelines are essential [12,16]. Still, a survey covering European countries demonstrated that medical associations published position papers about medical cannabis and cannabinoids in only three of them [11]. Given that cannabis use and patient demand are increasing, the unresolved issue of formulating clinical management guidelines should be addressed urgently by relevant medical associations in Poland.

Over 71% of physicians declared that their knowledge level about cannabinoids is “not” or “rather not” sufficient for patient counseling. Our finding that MDs self-evaluated knowledge about cannabinoids is not sufficient is repeatedly found in studies from other countries [12–28]. In Norway, 71% of surveyed physicians declared that they would like to be more knowledgeable about this topic [22]. Similarly, 74% of Canadian physicians felt not sufficiently informed about medical cannabis [24]. In another study conducted among physicians from Minnesota, 50% felt prepared for answering patient questions, and 77% were interested in learning more, in comparison with 92% of participants of our study [23]. In another study with a mixed group of HCPs (including pharmacists and nurses) involved in oncology care, the percentage of professionals who self-evaluated their knowledge level to be too low was 84%, similar to our findings [28].

Studies conducted among healthcare practitioners (including prospective HCPs) show that, even when the proportion of participants with enough confidence to counsel patients is relatively low, the support for the use of cannabinoids remains high for patients with short life expectancy or no alternatives for treatment [12,13,18,22]. This group encompasses terminal cancer patients and patients with symptoms refractory to standard treatment, such as cancer and neuropathic pain. In most studies among physicians, pain and cancer-related symptoms are most commonly mentioned as indications for cannabis use [12,13]. In an Irish study, 63.5% of physicians claimed that cannabinoids might be prescribed for pain management, and 68%-in terminal patients [18]. Additionally, 88% of physicians from Norway chose adverse effects of cancer treatment as an indication [22]. Similar findings described Gardiner et al. in their systematic review among oncologists and general practitioners [13].

Solid background education increases the confidence in using cannabinoids in clinical practice. Studies were also conducted among physicians in Europe, including those with either specialist training or those who received training in the treatment of addictions were more inclined towards using medical cannabis [12,18,22]. Furthermore, 70% of physicians from Canada indicated that they would be more comfortable if they had received any formal education [13]. Another systematic literature review of studies conducted among representatives of medical professions has demonstrated a lack of knowledge as a barrier for authorizing treatment with cannabis [13]. Results from these studies underline the importance of educational interventions that would explain basic scientific concepts and give practical instructions on how to use medical cannabis.

The lack of professional training declared by Polish physicians is concerning. Previous studies have found that the source of information consulted for healthcare professionals’ clinical practice is also questionable. Previous studies have shown that their primary source of knowledge was seldom medical courses or medical faculty, but rather media and the internet [12,13]. In a Norwegian study, news and television were the most frequently mentioned sources of knowledge, indicated by 39% of physicians, whereas medical literature was picked by roughly a quarter [22]. Likewise, a survey among Canadian hospital pharmacists demonstrated that most (66%) did not receive any formal education about cannabinoids. They also admitted that the sole educational resource available is an online self-study course [13]. News or websites dedicated to medical cannabis often raise unrealistic expectations about its properties and propagate information only partly based on medical literature. Furthermore, in reliable, evidence-based websites for Polish physicians, medical use of cannabinoids topic is somewhat absent. Access to professional training is also problematic for young adepts of medical sciences. Currently, medical curricula at Polish universities do not include the endocannabinoid system and pharmacology of cannabinoids. This problem could be solved by incorporating the pharmacological aspects
(including the ECS physiological and pathophysiological aspects) and clinical use as a part of pain treatment courses, free conferences run by regional medical chambers, and other independent sources of training for certified HCPs, and also by introducing these topics to curricula at Polish medical universities.

Our results show that there is a need for such educational interventions for Polish medical doctors. As indicated in previous studies, professional training encourages the use of cannabinoids. It is essential for patients for whom it is impossible to offer alternative treatments or available methods that were not well-tolerated. Proper training also helps medical professionals identify and advise against their use in patients for whom cannabinoids might be harmful. However, it is worth noting that a self-assessed level of knowledge, often used in such studies, should not be perceived as equal to a measure of competence. Previous research in various domains has shown that doctors tend to underestimate their actual level of knowledge or overestimate it, regardless of training and specialty and the domain of self-assessment [32]. Similar findings were the outcome of studies among other professions [33]. Therefore, self-evaluation is instead a measure of confidence than a factual knowledge level. A study by Zolotov et al. revealed that doctors who were more likely to recommend medical cannabis had less confidence in their knowledge about medical cannabis [15]. We agree with the authors that this could mean that individuals with higher awareness are more knowledgeable of the uncertainties regarding the medical uses of cannabinoids. In summary, these aspects should be considered when interpreting the results of our study.

In one of the previously conducted studies among medical students in Russia, religiousness significantly correlated with a more restrained approach to using cannabinoids in medicine; 57% of secular students declared they would recommend cannabis to a patient, in comparison with 27% of religious students ($p < 0.001$), and more often claimed it has positive effects on physical and mental health (54.3% vs. 28.2%; $p < 0.01$) [12]. Poland is considered a conservative country, with almost 89% of citizens declaring themselves as catholic, according to the Chief Statistical Office [34]. Interestingly, most physicians participating in the survey opted for solutions giving the most freedom when deciding how to approach a potential medical cannabis patient. Any restriction in prescribing, such as the requirement of having a specialist title, approval of regulatory body for medical cannabis treatment, or a formal requirement of obtaining a second opinion of a psychiatrist, was considered redundant. However, it is worth noting that they might have been taking into account other factors, such as long waiting times for additional consults, the cost for the patient, others which would cause a delay in initiating treatment. and, as a result, the alleviation of the patient’s ailments.

Nonetheless, in other European countries, such as the United Kingdom and Ireland, having a specialist title is one of the mandatory requirements for the prescription of cannabis [11,35]. The European Pain Federation (EFIC) report indicates that this state of affairs opposes trends found in other European countries. For the most part, medical cannabis is available to well-defined patient populations, and how it is dispensed is tightly controlled [11]. In several other countries, according to a report published by the European Pain Federation, access to medicinal cannabis is limited in other ways. For example, it is only available through compassionate use programs (in Sweden, Norway), or, although technically legal, the supply of cannabis for medicinal purposes is not available (in Slovenia) [11]. Poland, in contrast, presents a liberal approach to medical cannabis in the current legal framework, where there is no approved dosing indications list. The MoH requires no additional training or certificates for prescribing herbal cannabis. Therefore, the clinical decision to initiate treatment in each case and dosing or duration of treatment rely solely on the prescribing physician [36].

Contrary to prescribing controlled substances, such as cannabinoids in Poland, the restrictions are tighter in other medical fields. At times, the reasoning behind those regulations is difficult to understand. Before the COVID-19 pandemic, according to the act on preventing and combating infections and infectious diseases in Poland, performing
qualification for vaccination and the procedure itself was only possible for healthcare professionals who had attended an additional certified vaccination course or received this training during the specialization [37]. Although vaccine hesitancy is primarily based on the uncertainties regarding the safety profile of vaccines, the risk-benefit profile of vaccination in both the short- and long-term favors its use indisputably [38,39]. Vaccination is a very safe procedure, and no long-term side effects that would be unquestionably related to vaccination were identified [39]. Paradoxically, with current regulations, it is much easier for patients to buy opioids and cannabinoids, who now require only one visit to the doctor’s office and pharmacy before getting vaccinated. To receive a vaccine, at least two visits to the doctor’s office are necessary (one to get a prescription and then the other to get qualified for vaccination), and 1–2 visits at the pharmacy, depending on the availability of the vaccine.

Prescribing controlled substances is associated with the risk of developing dependence and abuse [40]. Additionally, in the case of opioids, abuse might result in fatal overdose in the sole 2019 in the USA, whereby more than 14,000 cases of deaths related to consumption of prescription opioids were recorded [40,41]. Even though the risk associated with medical uses of cannabinoids is incomparable to opioids, improper use can lead to addiction, traffic accidents, and risks to children who accidentally consume it [42–44]. Therefore, an optimal solution would embrace much tighter regulation of medical cannabis prescribing. In 2020, electronic prescriptions were introduced and made mandatory in Poland and replaced the paper form. This system allows physicians and patients to track prescriptions made in the past easily. It also requires the physician to confirm his identity before issuing any prescription via an official certificate or bank account [45]. Such a system could also enable rapid assessment of the situation and catch worrying phenomena related to prescription narcotic substances early on. In New York, mandatory electronic prescribing of controlled substances (including opioids) has reduced the number of prescriptions by 53% [46]. In Poland, to date, the consumption of medications using controlled substances is low (<2000 DDD for opioids), but there are some increasing trends observed for some of these substances, such as tramadol, which needs further monitoring [29]. Therefore, some control over prescriptions involving controlled substances should be warranted, which might be implemented as part of the electronic prescriptions system.

This study has some limitations. The most important is the small study size which does not enable a subgroup analysis to confront opinions of medical professionals of different backgrounds and identify associations of different demographic factors with participant’s decisions. A significant limitation is that we have only targeted physicians and not representatives of other medical professions such as nurses and pharmacists, who are also directly involved in patient care. Because it was an open survey, people with more interest in medical cannabis were more likely to participate, and, as a result, we might not have recruited a representative sample. The proportion of MDs with experience with recreational cannabis (39.9%) was higher than according to a survey conducted among the general Polish population aged 15–64 years (7.7% for females and 16.4% for males) [47]. It could have influenced the acceptance of cannabinoids as medicines and support for their legalization. However, considering that the participation was voluntary and anonymous, and that no tracking data were collected, the answers were more sincere than in the study conducted by National Bureau for Drug Prevention.

5. Conclusions

This study is the first insight into the perspectives of Polish physicians regarding the medical applications of cannabinoids. Most medical professionals have expressed their support for the medical use of cannabis and cannabinoids. However, the majority do not feel prepared for patient counseling, which is concerning. They could benefit from targeted educational interventions. Such interventions might encompass independent courses for licensed physicians, congresses, and websites. Additionally, this study has also identified physicians’ preferences and suggestions for stakeholders responsible for
shaping the policy regarding cannabis-based therapeutics. Further research is encouraged to investigate opinions and knowledge of the representatives of other medical professions (such as pharmacists, nurses, among others); to detect differences among representatives of different medical specialties, such as general practitioners, oncology, and pain specialists; and to identify factors contributing to their choices.

Author Contributions: Conceptualization, M.H. and J.J.; methodology, M.H., A.K. and J.J.; validation, M.C. and A.L.; formal analysis, M.H., J.J. and A.K.; investigation, M.H., A.L. and M.C.; resources, M.H., A.K. and J.J.; data curation, M.H.; writing—original draft preparation, M.H., J.J. and M.C.; writing—review and editing, A.K., A.L.; supervision, A.K., J.J.; project administration, M.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study protocol was prepared in line with the recommendations of the Helsinki Declaration and was approved by the Bioethics Committee of the Medical University of Warsaw. (IRB statement from the 3rd February 2020 number AKBE/22/2020).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Participation in the survey was anonymous and voluntary.

Data Availability Statement: Source data is available from the corresponding author upon a reasonable request.

Acknowledgments: The authors would like to thank their team who worked with us on this research, especially J.K., for his kind comments and guidance in drafting this article.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Internet-Based Law System. Act of the 7th of July 2017 Amending the Act on Counteracting Drug Addiction and the Act on Reimbursement of Medicines, Foodstuffs for Special Nutritional Purposes and Medical Devices. Available online: https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=wdu20170001458 (accessed on 13 June 2021).
2. List of Pharmaceutical Raw Materials Registered in the Republic of Poland Based on the Decision of the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. Available online: https://sf.rejestrymedyczne.csioz.gov.pl/?AspxAutoDetectCookieSupport=1#results (accessed on 3 May 2021).
3. Sativex SmPC 2012. Available online: https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/29034/characteristic (accessed on 13 June 2021).
4. Internet-Based Law System. Regulation of the Minister of Health of the 11th of September 2006 on Narcotic Drugs, Psychotropic Substances, Precursors of Category and Preparations Containing These Drugs or Substances. Available online: https://isap.sejm.gov.pl/isap.nsf/download.xsp/WDU20061691216/O/D20061216.pdf (accessed on 13 June 2021).
5. Internet-Based Law System. Regulation of the Minister of Health of the 17th of August 2018 on Psychotropic Substances, Narcotics, and New Psychoactive Substances List. Available online: https://isap.sejm.gov.pl/isap.nsf/download.xsp/WDU2018001591/O/D20181591.pdf (accessed on 13 June 2021).
6. Internet-Based Law System: Announcement of the Minister of Health of the 20th of January 2021 on the Announcement of the Consolidated Text of the Regulation of the Minister of Health on Narcotic Drugs, Psychotropic Substances, Precursors Category 1 and Preparations Containing These Drugs or Substances. Available online: https://isap.sejm.gov.pl/isap.nsf/download.xsp/WDU20210000166/O/D20210166.pdf (accessed on 13 June 2021).
7. Polish HTA Agency. Recommendation nr 39/2020 of 4th of August 2020. Available online: http://bipold.aotm.gov.pl/assets/files/zlecenia_mz/2020/099/REK/2020%20REK%2020%20Bedrolite.pdf (accessed on 5 June 2021).
8. Polish HTA Agency. Recommendation nr 69/2019 of 7th of November 2019. Available online: https://bipold.aotm.gov.pl/assets/files/zlecenia_mz/2019/124/REK/RP_69_2019_Bedrolite_Dravet.pdf (accessed on 5 June 2021).
9. Polish HTA Agency. Recommendation nr 80/2019 of 7th of November 2019. Available online: https://bipold.aotm.gov.pl/assets/files/zlecenia_mz/2019/138/REK/RP_80_2019_Bedrolite_zespol_Jacobse.pdf (accessed on 5 June 2021).
10. Polish HTA Agency. Recommendation nr 15/2018 of 26th of February 2018. Available online: https://bipold.aotm.gov.pl/assets/files/zlecenia_mz/2017/192/REK/RP_15_2018_kanabinoidy.pdf (accessed on 5 June 2021).
11. Krczvski-Skvorc, N.; Wells, C.; Häuser, W. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation. Eur. J. Pain 2018, 22, 440–454. [CrossRef] [PubMed]
12. Hordowicz, M.; Klimekiewicz, A.; Jarosz, J.; Wysocka, M.; Jastrzębska, M. Knowledge, attitudes, and prescribing patterns of cannabis and cannabinoid-containing medicines among European healthcare workers: A systematic literature review. Drug Alcohol Depend. 2021, 221, 108652. [CrossRef]  
13. Gardiner, K.M.; Singleton, J.A.; Sheridan, J.; Kyle, G.; Nissen, L. Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis—A systematic review. PLoS ONE 2019, 14, e0216556. [CrossRef]  
14. Karanges, E.A.; Suraev, A.; Elias, N.; Manocha, R.; McGregor, I.S. Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: A cross-sectional survey. BMJ Open 2018, 8, e022101. [CrossRef]  
15. Zolotov, Y.; Vullsoms, S.; Szmitran, S. Predicting Physicians’ Intentions to Recommend Medical Cannabis. J. Pain Symptom Manag. 2019, 58, 400–407. [CrossRef]  
16. Ziemlański, D.; Capler, R.; Tekanoff, R.; Lacasse, A.; Luconi, F.; Ware, M.A. Cannabis in medicine: A national educational needs assessment among Canadian physicians. BMC Med Educ. 2015, 15, 52. [CrossRef] [PubMed]  
17. Braun, I.M.; Wright, A.; Peteteet, J.; Meyer, F.L.; Yuppa, D.P.; Bolcic-Jankovic, D.; Leblanc, J.; Chang, Y.; Yu, L.; Nayak, M.M.; et al. Medical Oncologists’ Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study. J. Clin. Oncol. 2018, 36, 1957–1962. [CrossRef]  
18. Crowle, D.; Collins, C.; Delargy, I.; Laird, E.; Van Hoult, M.C. Irish general practitioner attitudes toward decriminalisation and medical use of cannabis: Results from a national survey. Harm Reduct. J. 2017, 14, 4. [CrossRef] [PubMed]  
19. Pereira, L.; Nunez-Iglesias, M.J.; Dominguez-Martis, E.M.; Lopez-Ares, D.; Gonzalez-Petreiro, M.; Novio, S. Nursing Students’ Knowledge and Attitudes Regarding Medical Marijuana: A Descriptive Cross-Sectional Study. Int. J. Environ. Res. Public Health 2020, 17, 2492. [CrossRef] [PubMed]  
20. Bielski, A.; Hus, A.; Sadowska, A.; Kosson, D. Study on the level of knowledge about medical marijuana among medical students. Wiad Lek. 2020, 73, 648–656. (In Polish) [CrossRef]  
21. Kusturica, M.P.; Tomas, A.; Sabo, A.; Tomić, Z.; Horvat, O. Medical cannabis: Knowledge and attitudes of prospective doctors in Serbia. Saudi. Pharm. J. 2018, 27, 320–325. [CrossRef] [PubMed]  
22. Arnfinson, J.L.; Kisa, A. Assessment of Norwegian physicians’ knowledge, experience and attitudes towards medical cannabis. Drugs: Educ. Prev. Policy 2021, 28, 165–171. [CrossRef]  
23. Philpot, L.; Ebbert, J.O.; Hurt, R.T. A survey of the attitudes, beliefs and knowledge about medical cannabis among primary care providers. BMC Fam. Pract. 2019, 20, 1–7. [CrossRef]  
24. Hewa-Gamage, D.; Blaschke, S.; Drosdowsky, A.; Koproski, T.; Braun, A.; Ellen, S. A Cross-sectional Survey of Health Professionals’ Attitudes towards Medicinal Cannabis Use as Part of Cancer Management. J. Law Med. 2019, 26, 815–824. [PubMed]  
25. Schwartz, R.H.; Voth, E.A.; Sheridan, M.J. Marijuana to Prevent Nausea and Vomiting in Cancer Patients: A Survey of Clinical Pharmacists. J. Clin. Med. 2021, 10, 4545. [CrossRef]  
26. Delbrin, R.E.; Kleiman, M.A. Marijuana as antiemetic medicine: A survey of oncologists’ experiences and attitudes. J. Clin. Oncol. 1991, 9, 1314–1319. [CrossRef]  
27. Costantino, R.C.; Felten, N.; Todd, M.; Maxwell, T.; McPherson, M.L. A Survey of Hospice Professionals Regarding Medical Cannabis Practices. J. Palliat. Med. 2019, 22, 1208–1212. [CrossRef]  
28. McLennan, A.; Kerba, M.; Subnis, U.; Campbell, T.; Carlson, L.E. Health Care Provider Preferences for, and Barriers to, Cannabis Use in Cancer Care. Curr. Oncol. 2020, 27, 199–205. [CrossRef] [PubMed]  
29. Bosetti, C.; Santucci, C.; Radrezza, S.; Erthal, J.; Berterame, S.; Corli, O. Trends in the consumption of opioids for the treatment of severe pain in Europe, 1990–2016. Eur. J. Pain 2019, 23, 697–707. [CrossRef]  
30. The Polish National Health Fund. Medical Professionals’ Workforce from Payer’s Point of View. Available online: https://www.nfz.gov.pl/download/gfx/nfz/pl/defaultstronaopisowa/349/42/1/kadra_medyczna_-_prezentacja.pdf (accessed on 24 July 2021).  
31. The Polish National Health Fund. Medical Professionals’ Workforce from Payer’s Point of View. Available online: https://www.gov.pl/web/zdrowie/komunikat-w-sprawie-kwalifikacji-osob-przeprowadzajacych-szczepienia-ochronne (accessed on 13 July 2021).
38. Karafillakis, E.; Larson, H.J. The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations. *Vaccine* 2017, 35, 4840–4850. [CrossRef] [PubMed]

39. Centers for Disease Control and Prevention (CDC). Safety of Vaccines. Available online: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html (accessed on 13 June 2021).

40. Preuss, C.V.; Kalava, A.; King, K.C. *Prescription of Controlled Substances: Benefits and Risks*; StatPearls Publishing: Treasure Island, FL, USA, 2021.

41. National Institute of Drug Abuse (NIDA). 2021; Overdose Death Rates. Available online: https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates (accessed on 13 July 2021).

42. Aydelotte, J.D.; Mardock, A.L.; Mancheski, C.A.; Quamar, S.M.; Teixeira, P.G.; Brown, C.V.; Brown, L. Fatal crashes in the 5 years after recreational marijuana legalization in Colorado and Washington. *Accid. Anal. Prev.* 2019, 132, 105284. [CrossRef] [PubMed]

43. Claudet, I.; Mouvier, S.; Labadie, M.; Manin, C.; Michard-Lenoir, A.-P.; Eyer, D.; Dufour, D.; Marie-Jeanne Study Group. Unintentional Cannabis Intoxication in Toddlers. *Pediatrics* 2017, 140, e20170017. [CrossRef] [PubMed]

44. Abu-Amna, M.; Salti, T.; Khoury, M.; Cohen, I.; Bar-Sela, G. Medical Cannabis in Oncology: A Valuable Unappreciated Remedy or an Undesirable Risk? *Curr. Treat. Options Oncol.* 2021, 22, 1–18. [CrossRef]

45. E-Health Center. Instruction Manual for the Electronic System of Prescriptions. Available online: https://gabinet.gov.pl/pdf/instrukcja (accessed on 24 August 2021).

46. Danovich, D.; Greenstein, J.; Chacko, J.; Hahn, B.; Ardolic, B.; Ilyaguyev, B.; Berwald, N. Effect of New York State Electronic Prescribing Mandate on Opioid Prescribing Patterns. *J. Emerg. Med.* 2019, 57, 156–161. [CrossRef]

47. National Bureau for Drug Prevention. Annual Report on the State of Drug Addiction in Poland. 2020. Available online: https://www.cinn.gov.pl/portal?id=15&res_id=1837081 (accessed on 24 August 2021).